Peng Katie sold $293K of SRRK

Peng Katie sold 5,446 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.56–$54.96, $0.29M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Peng Katie
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
high confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

Because the sale is pre-arranged and no new corporate event is disclosed, the trading signal is likely weak and mostly sentiment-driven.

02

Market read

Traders may note the insider sale, but there is no new fundamental catalyst in the text.

03

What to watch

The article provides no change in business outlook, only the transaction mechanics and post-sale holdings, limiting interpretability.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06 for a sale executed 2026-07-01

Background

The article is an SEC Form 4 insider transaction report for Scholar Rock Holding Corp, filed after trades executed under a 10b5-1 plan.

Company-level read

Ticker impact

$SRRKNeutralHigh confidence
Context

Scholar Rock Holding Corp disclosed a director open-market sale of 5,446 shares under a 10b5-1 plan, totaling about $293K.

Expected impact

Likely minimal immediate price impact; any effect is more about sentiment than new operating information.

Evidence & confidence

Form 4 details a director’s planned sale with no accompanying guidance, deal, or regulatory/operational change described in the text.

Market effects

No sector-wide implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

A director sale can still reflect liquidity needs rather than bearish expectations, especially when executed under a 10b5-1 plan.

Key entities

  • Scholar Rock Holding Corp

    Subject of the Form 4 insider transaction disclosure.

  • Peng Katie

    Director who sold shares via an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 8/10

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

$SRRKLow

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.